Friday, 16 October 2026European Markets

KITRON Stock Impressive Rise On Thursday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with KITRON (KIT.OL) rising 16.07% to kr38.88 on Thursday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.66% to kr1,415.32, following the last session's upward trend on what was a somewhat bullish trend trading session today.

KITRON's last close was kr33.50, 24.12% under its 52-week high of kr44.15.

About KITRON

Kitron ASA operates as an electronics manufacturing services company in Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, India, China, Malaysia, and the United States. It manufactures and sells electronics that are embedded in the customer's own products; and box-built electronic products. The company's services include development services, such as product development, product management, and re-engineering services; and industrialization services, including prototype manufacturing, evaluation of new products, component engineering and database, test development, design and build of high-level assembly lines, and environmental durability testing. Its services comprise sourcing and procurement services; manufacturing, assembling, and testing of electronic products for the professional market; redesign, repair, and maintenance, as well as logistics and distribution, and product deployment services. The company markets its services to connectivity, electrification, industry, medical devices, and defence/aerospace sectors. Kitron ASA was incorporated in 1996 and is headquartered in Billingstad, Norway.

Earnings Per Share

As for profitability, KITRON has a trailing twelve months EPS of kr2.99.

PE Ratio

KITRON has a trailing twelve months price to earnings ratio of 13. Meaning, the purchaser of the share is investing kr13 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.74%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, KITRON's stock is considered to be overbought (>=80).

Volatility

KITRON's last week, last month's, and last quarter's current intraday variation average was 1.19%, 0.18%, and 1.33%.

KITRON's highest amplitude of average volatility was 2.26% (last week), 1.25% (last month), and 1.33% (last quarter).

Yearly Top and Bottom Value

KITRON's stock is valued at kr38.88 at 22:32 EST, way under its 52-week high of kr44.15 and way above its 52-week low of kr27.32.

Revenue Growth

Year-on-year quarterly revenue growth declined by 8.8%, now sitting on 758.5M for the twelve trailing months.

More news about KITRON (KIT.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com